We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteomic Blood Test Predicts Cardiovascular Risk

By LabMedica International staff writers
Posted on 12 Apr 2022

A reliable, individualized, and dynamic surrogate of cardiovascular risk, synoptic for key biologic mechanisms, could shorten the path for drug development, enhance drug cost-effectiveness and improve patient outcomes. More...

A blood test has been developed that can predict whether someone is at high risk of a heart attack, stroke, heart failure or dying from one of these conditions within the next four years. The test, which relies of measurements of proteins in the blood, has roughly twice the accuracy of existing risk scores. It could enable doctors to determine whether patients’ existing medications are working or whether they need additional drugs to reduce their risk.

Scientist at SomaLogic Inc (Boulder, CO, USA) and their medical colleagues used highly multiplexed proteomics to address their objectives, measuring about 5,000 proteins in each of 32,130 archived plasma samples from 22,849 participants in nine clinical studies. They used machine learning to derive a 27-protein model predicting 4-year likelihood of myocardial infarction, stroke, heart failure, or death. The 27 proteins encompassed 10 biologic systems, and 12 were associated with relevant causal genetic traits. They independently validated results in 11,609 participants.

The SomaScan assay (SomaLogic Inc) uses DNA-based binding reagents (modified aptamers) to quantify the availability of binding epitopes on plasma proteins for about 5,000 proteins, with high specificity and limits of detection largely comparable to antibody-based assays. Briefly, the SomaScan assay started as a mix of thousands of fluorophore-labeled SOMAmer reagents immobilized on streptavidin-coated beads and incubated with 55 μL of EDTA plasma. SOMAmer reagents were hybridized to complementary sequences on a DNA microarray chip and quantified by fluorescence, which was related to the relative availability of the three-dimensional shape-charge epitope on each protein in the original sample. This integrates each protein’s abundance, shape, charge, and availability of the binding epitope.

The investigators reported that compared to a clinical model, the ratio of observed events in quintile 5 to quintile 1 was 6.7 for proteins versus 2.9 for the clinical model, AUCs were 0.73 versus 0.64, c-statistics were 0.71 versus 0.62, and the net reclassification index was +0.43. Adding the clinical model to the proteins only improved discrimination metrics by 0.01 to 0.02. Event rates in four predefined protein risk categories were 5.6%, 11.2%, 20.0%, and 43.4% within 4 years; median time to event was 1.71 years. Protein predictions were directionally concordant with changed outcomes. Adverse risks were predicted for aging, approaching an event, anthracycline chemotherapy, diabetes, smoking, rheumatoid arthritis, cancer history, cardiovascular disease, high systolic blood pressure, and lipids. Reduced risks were predicted for weight loss and exenatide. The 27-protein model has potential as a “universal” surrogate end point for cardiovascular risk.

Manuel Mayr, MD, PhD, a Professor of cardiovascular proteomics, said, “Proteins are the building blocks of our body. This study provides measurements for a quarter of all proteins that are encoded by our genes, which has become possible because of emerging, new technologies that allow measurement of thousands of proteins and offers new opportunities to assess risk in patients. While this study uncovers new associations between proteins in blood and death by all causes, more studies are needed to assess the potential clinical impact of using these 27 proteins, compared to current risk prediction tools for cardiovascular disease.” The study was published on April 6, 2022 in the journal Science Translation Medicine.

Related Links:
SomaLogic Inc 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.